Drugs / COVI-MSC
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04992247 | Feb → Jul 2024 | COVID-19 | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04903327 | Nov 2021 → Aug 2022 | COVID-19 | Sorrento Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04905836 | Nov 2021 → Dec 2022 | COVID-19 | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04909879 | Sep 2021 → Feb 2022 | acute respiratory distress syndrome | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04909892 | Aug 2021 → Jan 2022 | COVID-19 | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04728698 | Mar → Sep 2021 | COVID-19, acute respiratory distress syndrome | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVI-MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04903327 ↗ |
| Modality | Cell therapy | “Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)” NCT04728698 ↗ |
| Route | Intravenous | “Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells” NCT04728698 ↗ |